Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPX066 versus carbidopa/levodopa/entacapone in advanced Parkinson's disease
2009-017238-39Phase 3Completed
- Sponsor
- Impax Laboratories
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of carbidopa + levodopa and carbidopa + levodopa + entacapone in Parkinson's disease (PD) (2 arms), sponsored by Impax Laboratories. Primary endpoint: Percent off time during waking hours. Started Jul 2010; status: completed.
02
Drugs
carbidopa + levodopacarbidopa + levodopa + entacapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2009-017238-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017238-39.